Insider · SEC Form 4 filer
Eli Casdin
Past buys: 1 of 5 beat
Companies
Where they file as an insider
Standard Biotools (LAB) Director, 10% owner Latest filing Jun 18, 2026
GeneDx (WGS) Director, 10% owner Latest filing Jun 18, 2026
Biolife Solutions (BLFS) 10% owner Latest filing Aug 11, 2025
2seventy bio (TSVT) Director Latest filing May 13, 2025
SomaLogic (SLGC) Director, 10% owner Latest filing Jan 5, 2024
EQRx (EQRX) 10% owner Latest filing Nov 9, 2023
Track record
Did their buys beat the typical stock?
Open-market buys19
Quarters checked 6 months later5
Beat the typical stock 1 of 5
Quarters too new to check1
1 of 5 checked quarters beat the typical stock. A past record is data, not a forecast.
GeneDx (WGS) Bought Jun 4–5, 2026 · $11.1M · 200,000 shares Too new Too new. Its 6-month check uses prices as of Dec 31, 2026.
Standard Biotools (LAB) Bought Nov 18–20, 2025 · $1.37M · 1.07M shares Behind typical Dec 31, 2025 $1.28 → Jun 30, 2026 $0.82 · −35.7% (typical stock +4.7%)
Standard Biotools (LAB) Bought Aug 13–Sep 4, 2025 · $1.08M · 858,220 shares Behind typical Sep 30, 2025 $1.30 → Mar 31, 2026 $0.92 · −29.3% (typical stock −3.4%)
Standard Biotools (LAB) Bought Aug 2–5, 2024 · $1.95M · 1.2M shares Behind typical Sep 30, 2024 $1.93 → Mar 31, 2025 $1.08 · −44.0% (typical stock −7.5%)
GeneDx (WGS) Bought May 23–29, 2024 · $4.27M · 210,000 shares Beat typical Jun 30, 2024 $26.14 → Dec 31, 2024 $76.86 · +194.0% (typical stock +3.9%)
Standard Biotools (LAB) Bought May 15–17, 2024 · $3.46M · 1.35M shares Behind typical Jun 30, 2024 $1.77 → Dec 31, 2024 $1.75 · −1.1% (typical stock +3.9%)
Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.
Past results. This is data, not advice.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.